Clairity raises $43m to fuel US rollout of AI breast cancer platform
Clairity Breast is claimed to be the first FDA-authorised platform for predicting a woman’s five‑year risk of developing breast cancer via mammogram analysis.
14 November 2025
14 November 2025
Clairity Breast is claimed to be the first FDA-authorised platform for predicting a woman’s five‑year risk of developing breast cancer via mammogram analysis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.